Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The supplements are made using only vegetarian-sourced ingredients
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
Subscribe To Our Newsletter & Stay Updated